Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer: equality impact assessment - guidance Epidermal ...
The systematic review was carried out to identify evidence on the technical performance and clinical effectiveness of the different options available to detect epidermal growth factor receptor ...
Association between patient tumour characteristics and five-year survival in Nigerian patients with breast cancer.
“イレッサ”、及び化学療法のいずれも以下の因子がILDの危険因子とされた。喫煙歴、既存の間質性肺炎、診断よりILD発症までの期間が6カ月以内、WHOのPS2以上、正常肺占有率が50％以下、年齢55歳以上、心血管系の合併症を有しているなどであった（表1）。
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC SEOUL, ...
Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns ...
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO ® (osimertinib) demonstrated a statistically significant and highly clinically ...
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC At AACR ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する